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DOI 10.1016/j.stem.2009.05.005To date, all methods to generate induced
pluripotent stem cells (iPSCs) require the
use of genetic materials and/or potentially
mutagenic molecules. Here we report the
generation of stable iPSCs from human
fibroblasts by directly delivering four re-
programming proteins (Oct4, Sox2, Klf4,
and c-Myc) fused with a cell-penetrating
peptide (CPP). These protein-induced
human iPSCs (p-hiPSCs) exhibited simi-
larity to human embryonic stem cells
(hESCs) in morphology, proliferation, and
expression of characteristic pluripotency
markers. p-hiPSC lines produced with
these recombinantproteinswere success-
fullymaintained formore than35passages
and differentiated into derivatives of all
three embryonic germ layers both in vitro
and in teratomas. This system eliminates
the potential risks associated with the use
of viruses, DNA transfection, and poten-
tially harmful chemicals and in the future
could potentially provide a safe source of
patient-specific cells for regenerative
medicine.
Over a decade ago, Wilmut and
colleagues showed that adult somatic
cells could be reprogrammed back to an
undifferentiated embryonic state using
somatic cell nuclear transfer (SCNT) (Wil-
mut et al., 1997). However, since that
time, attempts togenerate patient-specific
cells using SCNT have proven unsuccess-
ful (Chung et al., 2009; French et al., 2008).
In 2006, a new and less controversial
method of reprogramming somatic cells
to pluripotency was reported by viral
expression of the transcription factors
Oct4, Sox2, Klf4, and c-Myc (Takahashi
and Yamanaka, 2006). This and subse-
quent studies confirmed that mouse and
human somatic cells can be reprog-
rammed to the pluripotent state via viral472 Cell Stem Cell 4, June 5, 2009 ª2009 Etransduction with the same or similar sets
of reprogramming factors (Maherali et al.,
2007; Okita et al., 2007; Park et al., 2008;
Takahashi et al., 2007; Wernig et al.,
2007; Yu et al., 2007). Although the thera-
peutic potential of iPSCshasbeendemon-
strated in animal models of sickle cell
anemia and Parkinson’s disease (Hanna
et al., 2007;Wernig et al., 2008), these cells
contain multiple viral vector integrations
that make them unsuitable for human clin-
ical trials. The use of genome-integrating
viruses could cause insertional mutagen-
esis and unpredictable genetic dysfunc-
tion (Okita et al., 2007; Yamanaka, 2007).
To address whether it is possible to
generate hiPSCs without the use of viral
or DNA vectors, we attempted to deliver
four reprogramming proteins—Oct4,
Sox2, Klf4, and c-Myc—directly into
somatic cells. A major hurdle for intracel-
lular delivery of macromolecules such as
proteins is their limited ability to cross
the cellular membrane (Belting et al.,
2005). In 1988, Frankel and Pabo found
that the human immunodeficiency virus
transactivator of transcription (HIV-TAT)
protein can overcome this hurdle with
a short basic segment residing at amino
acids 48–60 that allows this protein to
penetrate the cell membrane and activate
HIV-specific genes (Frankel et al., 1988;
Frankel and Pabo, 1988). This and other
naturally occurring peptides capable of
overcoming the cell membrane barrier
contain a high proportion of basic amino
acids (e.g., arginine or lysine) and are
known as CPPs (El-Sayed et al., 2009;
Ziegler et al., 2005). In order to test our
hypothesis that CPP-anchored reprog-
ramming proteins may directly reprogram
human somatic cells without genetic
manipulation and/or chemical treatments,lsevier Inc.we first examined whether red fluorescent
protein (RFP) fusedwith a 9 arginine (RFP-
9R) (Wender et al., 2000) could penetrate
into COS-7 cells and human newborn
fibroblasts (HNFs). RFP-9Rwas efficiently
delivered into both cell types within a few
hours, even when in the context of whole-
cell extracts (see Figure S1 available on-
line). We then generated stable HEK293
cell lines that could express each of
the four human reprogramming factors
(Oct4, Sox2, Klf4, and c-Myc) fused with
9R and the myc tag. High expression of
these proteins was confirmed in HEK293
cell lines by western blotting analyses
(Figure S2). When HNFs were treated
with cell extracts from the HEK293 cell
lines, efficient intracellular translocation
of each recombinant protein was ob-
served within 8 hr (Figure 1A). Notably, in
contrast to RFP-9R, which was translo-
cated to the cytoplasm, it appeared
that most recombinant reprogramming
proteins were translocated to the nucleus,
while some remained in the cytoplasm
(Figure 1A and Figure S1).
In an initial series of experiments, 5 3
105 HNFs were treated with combined
total extracts of four HEK293 cell lines
for 16 hr (see ‘‘Protocol 1’’ in Figure S3).
After washing, cells were incubated for 6
days in ES media 1 and then transferred
onto mouse embryonic feeders (MEFs).
The transferred cells were incubated
with ES media 2 for up to 4 weeks.
Despite numerous attempts, we did not
observe the formation of reprogrammed
colonies using this protocol. We next
treated with the same total extracts for
16 hr followed by washing and incubation
with ES media 1 for 8 hr/day for 6 days
(‘‘Protocol 2’’ in Figure S3). By day 7,
most cells did not survive, and no colonies
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One potential reason for the lack of
success is that, in contrast to virus- or
other DNA-based methods, the reprog-
ramming factors were not provided
continuously and thus were in short
supply. Therefore, we tested whether
repeated protein treatment cycles (16 hr
protein treatment followed by 6 day incu-
bation in ES media 1) (Figure 1B) could
yield hiPSCs. Using this approach, after
three or four rounds of treatment, several
colonies with iPSC-like morphology were
observed (Figure 1C), although none of
these colonies showed alkaline phospha-
tase (AP) activity, suggesting only rudi-
mentary reprogramming. When this
procedure was repeated for further
cycles, the number of iPSC-like colonies
significantly increased, and approxi-
mately half of the resulting colonies were
AP positive starting from the sixth cycle
(Figure 1D). In contrast, no such colonies
were formed at any stage when extracts
of naive HEK293 cells were used. AP-pos-
itive colonies with iPSC-like morphology
were handpicked and transferred onto
MEFs in the presence of ES media 2 and
ES media 3 for 7 days each. Five hiPSC-
like colonies were established, and two
of them were maintained and character-
ized in this study. These two cell lines
(p-hiPS01 and p-hiPS02) have been
successfully maintained for more than 35
passages and exhibit morphology similar
to that of hESCs, characterized by large
nuclei and scant cytoplasm (Figure 1C).
Overall, the establishment of these
hiPSC-like colonies took about 8 weeks,
approximately double that seen with viral
transduction (Park et al., 2008; Takahashi
et al., 2007; Yu et al., 2007). At present,
the efficiency of hiPSC generation is
significantly lower using this protein-
based protocol (about 0.001% of input
cells; Figure 1D), compared to virus-based
Figure 1. Generation of Protein-Induced hiPSC Lines by Direct Delivery of Reprogramming
Proteins Fused with 9R as a CPP
(A) HNFs were incubated with HEK293 extracts expressing each reprogramming protein and subjected to
immunocytochemistry using myc antibodies. Nuclei were counterstained with DAPI.
(B) The schematic protocol depicts a repeated process and the timeline for generating p-hiPSCs from
HNFs.
(C) (Top panel) Shown are starting HNFs (first image), morphology after three cycle protein treatments
(second image), and increased colony number after six cycles (third image). Approximately half of these
iPS-like colonies stained positive for AP; early morphology after p-hiPSC colonies were transferred to
MEF is shown (fourth image); and morphology of
established p-hiPSC line is shown at passage
number 10 (p-hiPS01 [fifth image] and p-hiPS02
[sixth image]). Immunostaining of p-hiPS01 (middle
panel) and p-hiPS02 (bottom panel) clones show
expression of hESC markers, including AP,
SSEA-3, SSEA-4, Oct-4, Nanog, and TRA-1-60.
Nuclei were stained with DAPI (blue in second
and third row of panel).
(D) Shown is efficiency of reprogrammed colony
formation with iPS-like morphology and AP-posi-
tive staining after different numbers of the protein
treatment cycle. This is the summary of three
independent experiments with the standard error.Cell Stem Cell 4, June 5, 2009 ª2009 Elsevier Inc. 473
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(A) Quantitative RT-PCR was performed to assess the expression of c-Myc, Gdf-3, Klf4, Nanog, Oct4, Rex1, Sox2, and hTERT in p-hiPS01 and p-hiPS02, hES
(H9), and HNF cells. Relative gene expression represents fold changes relative to that of HNF cells normalized to b-actin expression. This experiment (repeated
twice in triplicate using independently prepared cDNAs) resulted in almost identical patterns.
(B) The global gene-expression patterns were compared between p-hiPS01 and HNF, and between p-hiPS01 and H9 with Affymetrix microarrays. The red lines
indicate the diagonal and 5-fold changes between the paired samples.
(C) Bisulfite sequencing analysis of the Nanog and Oct4 promoters reveals almost complete epigenetic reprogramming. Open and closed circles indicate unme-
thylated and methylated CpG, respectively. Numbers on top show each CpG location. Percentages of CpG methylation (%Me) are shown.
(D) In vitro differentiation of p-hiPSCs. Immunostaining images (first and second row panels) show all three germ layer cells at day 24, including neural
(ectodermal), muscle and endothelial-like (mesodermal), and endoderm-like cells (endoderm).
(E) Teratoma formation in immunodeficiencymice by p-hiPSCs. H&E staining was performed for teratomas. The resulting teratomas contained tissues represent-
ing all three germ layers (p-hiPS01, first row; and p-hiPS02, second row): ectoderm, epidermal and neural tissue (rosette); mesoderm, bone and cartilage; and
endoderm, respiratory epithelium and intestinal-like epithelium.protocols (about 0.01% of input cells)
(Park et al., 2008; Takahashi et al., 2007;
Yu et al., 2007).
In order to determine whether the
p-hiPSCs have hESC-like properties, we
examined them for expression of markers
of pluripotency. As shown in Figure 1C,
both cell lines prominently expressed
ESC markers, including AP, Oct4, Nanog,
tumor-rejection antigen (TRA)1-60, stage-
specific embryonic antigen (SSEA)-3, and
SSEA-4.Quantitative reverse transcription
PCR (qRT-PCR) analysis confirmed that
both lines expressed endogenousmRNAs
of ESC markers: Oct4, Nanog, Sox2,
reduced expression 1 (Rex1), growth and
differentiation factor 3 (Gdf3), and telome-
rase reverse transcriptase (hTERT) levels
were dramatically higher than those of474 Cell Stem Cell 4, June 5, 2009 ª2009 EHNF cells (up to 100-fold, and comparable
to hESCs) (Figure 2A). The expression
patterns of ESC pluripotency markers
were indistinguishable from hESCs (H9),
strongly suggesting that appropriate
epigenetic reprogramming had occurred
in the p-hiPSCs. Bisulfite sequencing ana-
lyses further showed that the promoter
regions of the pluripotency genes Nanog
and Oct4 were significantly demethylated
in both p-hiPSC lines and the hESC H9
line, whereas the same regions were
densely methylated in the parental HNF
cells (Figure 2C). hiPSC lines from the
starting HNFs were also generated using
retroviral vectors expressing the same
four reprogramming factors (Park et al.,
2008; Takahashi et al., 2007; Yu et al.,
2007). These cells displayed similar char-lsevier Inc.acteristics and properties as the p-hiPSCs
(Figure S4), and one of them (rv-hiPS01)
was used as a control. When global gene
expression was compared using the Affy-
metrix Array U133 Plus 2.0, analyzing
over 47,000 human transcripts, both
p-hiPSC and rv-hiPS01 showed high simi-
larity to hES H9, but not to HNFs
(Figure 2B, Figure S5). Since hES H9 and
rv-hiPS01 were used as control cell lines,
it was important to rule out the possibility
that the new p-hiPSCs were derived from
contaminating cells. RT-PCRanalyses de-
tected all four transgene mRNAs in rv-
hiPS01 cells, but not in p-hiPS01 and
p-hiPS02 cell lines (Figure S6). Further-
more, DNA fingerprinting demonstrated
that the patterns of both p-hiPSC lines
and rv-hiPS01 cells were identical to the
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of the hES (H9) cells and HEK293 cells
(Figure S7), thus confirming that both
p-hiPSC lines are derived from HNF cells.
Both p-hiPSC lines exhibited the same
karyotype as the starting HNF cells
(Figure S8).
When the p-hiPSCs were allowed to
form embryoid bodies (EBs) by suspen-
sion culture, they readily differentiated
into cells of all three germ layers
(Figure 2D, Figure S8). After 8 days, well-
formed EB structures were observed
from both p-hiPSC clones. When these
EB-like structures were incubated on
gelatin-coated tissue culture plates in
ITSFnmedia for 15–25 days, they differen-
tiated to a wide range of cell types,
including neural, muscle, and endodermal
cells, among others. Immunocytochem-
ical analyses demonstrated the existence
of different cell types positive for
hepatocyte necrosis factor 3b (HNF 3b,
endoderm marker), a-fetoprotein (AFP,
endoderm marker), smooth-muscle actin
(SMA,mesodermmarker), desmin (meso-
derm marker), Tuj1 (ectoderm marker),
nestin (ectoderm marker), and tyrosine
hydroxylase (TH, ectoderm marker)
(Figure 2D, Figure S8). In addition, tera-
toma formation was observed after trans-
plantation of p-hiPSCs under the kidney
capsule of nude mice for 6–8 weeks.
These teratomas contained tissues from
all three germ layers including neural
tissues (ectoderm), epidermal tissues
(ectoderm), striated muscle (mesoderm),
adipose tissue (mesoderm), cartilage
(mesoderm), respiratory epithelium (endo-
derm), and intestinal-like epithelial tissues
(endoderm) (Figure 2E, Figure S8), con-
firming that both p-hiPSC clones exhibit
pluripotency both in vitro and in vivo.
Protein-based hiPSC technology offers
a new and potentially safe method for
generating patient-specific stem cells
that does not require the destruction of
ex utero embryos. This systemcompletely
eliminates genomemanipulation andDNA
transfection, resulting in human iPSCs
suitable for drug discovery, disease
modeling, and future clinical translation.
In this regard, the present study demon-
strates the ‘‘proof of concept’’ that human
iPSCs can be generated by direct protein
delivery without genetic manipulation.
Other studies suggest that it may be
possible to replace and/or further reduce
the number of factors required for reprog-ramming (Huangfu et al., 2008; Li et al.,
2009; Shi et al., 2008). To minimize/avoid
chromosomal disruption, adenovirus and
plasmid transfection have been success-
fully used to generate iPSCs in the mouse
system (Kaji et al., 2009;Okita et al., 2008).
Also, Thomson and his colleagues re-
ported generation of hiPSCs by transfec-
tion with nonintegrating episomal vectors
(Yu et al., 2009). In addition, piggyBac
transposon (Kaji et al., 2009; Woltjen
et al., 2009) and Cre-recombinase excis-
able viruses (Soldner et al., 2009) have
been used to generate hiPSCs. While
the transgenes can be excised by induc-
ible gene expression once reprogram-
ming is established (Soldner et al., 2009;
Stadtfeld et al., 2008; Woltjen et al.,
2009), residual sequences and chromo-
somal disruptions may still result in harm-
ful alterations that could pose clinical
risks.
The DNA vector-free, direct protein
transduction system described here elim-
inates limitations that may be caused by
viral or any other DNA-based reprogram-
ming methods. However, the generation
of p-hiPSCs is very slow and inefficient
and requires further optimization. In
particular, the whole-protein extracts
used in the present study limited the
concentrations of factors delivered into
the target cells, thus suggesting that
p-hiPSCsmaybemoreefficientlygenerated
using purified reprogramming proteins.
Recently, Ding and his colleagues re-
ported the generation of mouse iPSCs by
combining the use of recombinant repro-
grammingproteins and thesmallmolecule
valproic acid (Zhou et al., 2009). In this
study, mouse iPSCs were not generated
when only recombinant proteins were
used. In contrast, the system described
here generated human iPSCs with direct
delivery of reprogramming proteins in the
absence of any chemical treatment. One
possible explanation for these differences
is that we used reprogramming proteins
expressed in mammalian cells, while
Ding and colleagues used refolded
proteins after expression in E. coli. Since
chemicals such as valproic acid and/or
genetic manipulation may induce muta-
tions, it has been suggested that whole
genomic sequencing would be necessary
if such methods are used to generate
iPSCs (Yamanaka, 2009). In conclusion,
the system described here eliminates the
potential risks associated with chromo-Cell Stem Csomal integrations and/or mutations and
may allow the translation of hiPSC tech-
nology into the clinic.
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